Based on the estimated incidence rates of different pediatric tumors in the US and prevalence of KRAS alterations observed in our cohort, we estimate the highest incidence of KRAS altered cases to be in acute leukemia (n = 553), followed by colorectal (n = 88), ovary (n = 71), and glioma (n = 64; Supplemental Table 1). This evidence concerns the gene KRAS and acute leukemia.